Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study

Autor: S V Morozova, Ludmila M. Antonenko, Matsnev Ei, Volodymyr Golyk, Maksym I. Situkho, O. A. Melnikov, Maxim V. Zamergrad, Vasyl I. Popovych, Olena I. Asaulenko, E.E. Sigaleva, Vladimir Anatolyevich Parfenov
Rok vydání: 2016
Předmět:
Male
Medical Doctors
Physiology
Health Care Providers
lcsh:Medicine
Otology
Pathology and Laboratory Medicine
Russia
Geographical Locations
0302 clinical medicine
Vertigo
Medicine and Health Sciences
Betahistine
Prospective Studies
030223 otorhinolaryngology
Prospective cohort study
lcsh:Science
Multidisciplinary
biology
Pharmaceutics
Nausea
Middle Aged
Europe
Professions
Research Design
Vomiting
Female
Vestibule
Labyrinth
medicine.symptom
Ukraine
medicine.drug
Research Article
Adult
medicine.medical_specialty
Asia
Clinical Research Design
Research and Analysis Methods
Drug Administration Schedule
03 medical and health sciences
Pharmacotherapy
Signs and Symptoms
Drug Therapy
Diagnostic Medicine
Internal medicine
Physicians
medicine
otorhinolaryngologic diseases
Humans
Adverse effect
Aged
business.industry
lcsh:R
Biology and Life Sciences
biology.organism_classification
Discontinuation
Health Care
Otorhinolaryngology
People and Places
Physical therapy
Quality of Life
lcsh:Q
Population Groupings
sense organs
Adverse Events
business
Physiological Processes
030217 neurology & neurosurgery
Zdroj: PLoS ONE
PLoS ONE, Vol 12, Iss 3, p e0174114 (2017)
ISSN: 1932-6203
Popis: Background Vestibular vertigo is associated with substantially reduced quality of life. Betahistine is effective in improving vertigo-associated symptoms, with longer treatment periods leading to greater improvements; however, it is not known whether these effects persist after treatment cessation. Methods VIRTUOSO was a prospective, multinational, non-comparative, post-marketing observational programme investigating the effectiveness of betahistine (48 mg/day) and the course of vertigo after the discontinuation of treatment. Patients with vestibular vertigo who were prescribed 48 mg/day betahistine were enrolled in Russia and Ukraine. Treatment duration was up to 2 months, and patients were followed up for 2 months after discontinuation of betahistine. Efficacy endpoints included clinical response (assessed by change in vertigo severity), monthly attack frequency, and physician and patient grading of overall clinical response and improvement of vertigo-associated symptoms. Results Overall, 309 patients were enrolled and 305 completed the study. Clinical response was rated as good, very good or excellent in 74.1% of patients at end of treatment, with vertigo severity significantly decreased from baseline (p < 0.001). Monthly vertigo attack frequency decreased significantly during the 2 months of treatment (p < 0.001 from baseline) and further decreased during the 2-month follow-up (p < 0.001 from end of treatment). Overall, clinical response was graded as good or excellent by 94.4% of physicians and 95.4% of patients. Clinical improvement was considered either good or excellent by 82.6–90.5% of physicians and patients for nausea, vomiting and faintness. Only one adverse event was reported, with no serious adverse events. Conclusion Our findings suggest that betahistine (48 mg/day) therapy is effective in treating vertigo in routine clinical settings. The observed effects persisted for 2 months after treatment cessation, suggesting that betahistine may facilitate lasting vestibular compensation.
Databáze: OpenAIRE
Externí odkaz: